- Genmab shares rose 28% on Wednesday
- petosemtamab plus Keytruda cut death risk by half in late-stage head and neck cancer trial
Genmab's experimental drug petosemtamab, combined with Merck's Keytruda, halved the risk of death in a late-stage head and neck cancer study. Shares surged 28%. Median survival data not yet disclosed.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.